Presentation and Webcast Held Friday, March 28 at 2:30 p.m. Eastern Time
PLYMOUTH, Mich.--(BUSINESS WIRE)--
Esperion Therapeutics, Inc. (NASDAQ: ESPR), a clinical-stage
biopharmaceutical company focused on developing and commercializing
first-in-class, oral, low-density lipoprotein cholesterol (LDL-C)
lowering therapies for the treatment of hypercholesterolemia, today
announced that Tim M. Mayleben, Esperion's president and chief executive
officer, will present at the 21st Annual BioCentury Future
Leaders in the Biotech Industry conference in New York City. The
presentation and webcast will take place on Friday, March 28, 2014 at
2:30 p.m. Eastern Time.
A live, listen-only webcast of the presentation can be accessed on the
investor relations section of the Esperion website at investor.esperion.com/events.
A webcast replay of the call will be available approximately two hours
after completion of the call and will be archived on the Company's
website for 90 days following the event.
About Esperion Therapeutics
Esperion Therapeutics, Inc. is a clinical stage biopharmaceutical
company focused on developing and commercializing first-in-class, oral,
low-density lipoprotein cholesterol (LDL-C) lowering therapies for the
treatment of patients with hypercholesterolemia and other
cardiometabolic risk markers. ETC-1002, Esperion's lead product
candidate, is a unique, first-in-class, orally available, once-daily
small molecule designed to lower LDL-cholesterol levels and avoid the
side effects associated with the currently-available LDL-cholesterol
lowering therapies. ETC-1002 is being developed primarily for patients
intolerant of statins with elevated levels of LDL-cholesterol. Phase 2b
clinical trials for ETC-1002 are currently underway and build upon a
successful and comprehensive Phase 1 and Phase 2 program. For more
information, please visit www.esperion.com.
Media Contact:
W2O Group
Elliot Fox, 212.257.6724
efox@w2ogroup.com
Source: Esperion Therapeutics, Inc.
News Provided by Acquire Media